Janssen Pharmaceutica v. Teva Pharmaceuticals USA, Inc. (In re ‘318 Patent Infringement Litigation)

583 F.3d 1317 (2009)

From our private database of 46,500+ case briefs, written and edited by humans—never with AI.

Janssen Pharmaceutica v. Teva Pharmaceuticals USA, Inc. (In re ‘318 Patent Infringement Litigation)

United States Court of Appeals for the Federal Circuit
583 F.3d 1317 (2009)

Play video

Facts

Bonnie Davis applied for a patent on a method of treating Alzheimer’s disease using a molecule compound called galanthamine. The patent application’s specification cited papers on animal testing that suggested positive effects of galanthamine on memory. The United States Patent and Trademark Office (PTO) initially rejected Davis’s application on the ground of obviousness in light of the animal studies. Davis responded that the cited testing was conducted on animals with normal brains—that is, under conditions with no relevance to Alzheimer’s. However, Davis added that new testing was underway that would more directly address the effects of galanthamine on Alzheimer’s. The patent (the ‘318 patent) was issued in May 1987. The testing referred to by Davis was completed in July 1987. Davis licensed the patent to Janssen Pharmaceutica (Janssen) (plaintiff) in 1995. Janssen received government approval to market galanthamine as an Alzheimer’s treatment in 2001. A few years later, Janssen sued several generic drug manufacturers for infringement of the ‘318 patent. The actions were consolidated. The federal district court held that the ’318 patent was invalid on the grounds that (1) the relevant animal testing was not complete at the time of its issuance and (2) the specification and claims failed to teach the use of the claimed method, including dosage information. Janssen appealed to the United States Court of Appeals for the Federal Circuit.

Rule of Law

Issue

Holding and Reasoning (Dyk, J.)

What to do next…

  1. Unlock this case brief with a free (no-commitment) trial membership of Quimbee.

    You’ll be in good company: Quimbee is one of the most widely used and trusted sites for law students, serving more than 832,000 law students since 2011. Some law schools even subscribe directly to Quimbee for all their law students.

  2. Learn more about Quimbee’s unique (and proven) approach to achieving great grades at law school.

    Quimbee is a company hell-bent on one thing: helping you get an “A” in every course you take in law school, so you can graduate at the top of your class and get a high-paying law job. We’re not just a study aid for law students; we’re the study aid for law students.

Here's why 832,000 law students have relied on our case briefs:

  • Written by law professors and practitioners, not other law students. 46,500 briefs, keyed to 994 casebooks. Top-notch customer support.
  • The right amount of information, includes the facts, issues, rule of law, holding and reasoning, and any concurrences and dissents.
  • Access in your classes, works on your mobile and tablet. Massive library of related video lessons and high quality multiple-choice questions.
  • Easy to use, uniform format for every case brief. Written in plain English, not in legalese. Our briefs summarize and simplify; they don’t just repeat the court’s language.

Access this case brief for FREE

With a 7-day free trial membership
Here's why 832,000 law students have relied on our case briefs:
  • Reliable - written by law professors and practitioners, not other law students
  • The right length and amount of information - includes the facts, issue, rule of law, holding and reasoning, and any concurrences and dissents
  • Access in your class - works on your mobile and tablet
  • 46,500 briefs - keyed to 994 casebooks
  • Uniform format for every case brief
  • Written in plain English - not in legalese and not just repeating the court's language
  • Massive library of related video lessons - and practice questions
  • Top-notch customer support

Access this case brief for FREE

With a 7-day free trial membership